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Abstract
Rare endocrine pathology is manifested by either a deficiency or excess of one or more hormones. These conditions can be
life-threatening and are almost universally associated with long-term morbidity. Understanding the aetiology of these
conditions requires multicentre collaboration and expertise, most often across national boundaries, with the capacity for
long-term follow-up. The EuRRECa (European Registries for Rare Endocrine Conditions) project (www.eurreca.net),
funded by the EU Health Programme, aims to support the needs of the wider endocrine community by maximising the
opportunity for collaboration between patients, health care professionals and researchers across Europe and beyond. At the
heart of the EuRRECa collaboration is a Core Endocrine Registry that collects a core dataset for all rare endocrine conditions
that are covered within Endo-ERN. The registry incorporates patient reported markers of clinical outcome and will signpost
participants to high-quality, disease-specific registries. Furthermore, an electronic surveillance programme (e-REC) captures
clinical activity and epidemiology for these rare conditions. EuRRECa receives guidance compliant with the highest ethical
standards from Expert Working Groups that align with the Main Thematic Groups of Endo-ERN. Security, data quality and
data governance are cornerstones of this platform. Clear policies that are acceptable to patients, researchers and industry for
data governance coupled with widespread dissemination and knowledge exchange through closely affiliated stakeholders
will ensure sustainability beyond the current lifetime of the project. This paper describes the infrastructure that has been
developed, stakeholder involvement, the data fields that are captured within the registry and details on the process for using
the platform.
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Background
Endocrine conditions are often associated with chronic
long-term morbidity and optimal management of these
conditions requires specific expertise and the capacity for
long-term follow-up in expert centres providing multi-
disciplinary care. Lack of expert and evidence-based care,
particularly in rare conditions, can result in substantial
variation in patient care. Registries have the potential to
improve patient care by enabling pooling of data and
facilitating surveillance, audit and research via a virtual
environment [1]. The importance of international registra-
tion of patients with rare conditions is widely recognised
and supported by the European Union [2], with several
European initiatives including Orphanet and RD-Connect
highlighting existing registries [3, 4].
The recent development of the European Reference
Network for Rare Endocrine Conditions (Endo-ERN)
(endo-ern.eu), has provided an opportunity to consider how
to pool resources and develop a virtual environment that
serves the objectives of this ERN and acts as a model for the
wider endocrine community and beyond. Endo-ERN is the
largest ERN with 71 Reference Centres from 19 member
states that are estimated to care for over 60,000 patients.
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Endo-ERN includes 36 groups of conditions with orpha-
codes that are organised into eight ‘Main Thematic Groups’
[5]. The European Commission states that ERNs require
established frameworks for the gathering of standardised
information on established outcomes, process indicators and
patient registries [6]. Endo-ERN is able to act as a model for
a large group of rare conditions that require a common Core
Endocrine Registry (CER) and an electronic surveillance
system to capture activity, epidemiology and natural history
of these conditions.
The concept of EuRRECa
EuRRECa (https://eurreca.net/) was launched in February
2018 and is funded by the EU Health Programme and is
also supported by the European Society for Paediatric
Endocrinology (ESPE) and the European Society of
Endocrinology (ESE). It aims to maximise the opportunity
for patients, health care professionals and researchers to
participate and use high‐quality, patient-centred registries
for rare endocrine conditions that are covered within Endo‐
ERN. Participation is open to all members of Endo-ERN
and to all other professionals providing endocrine care.
EuRRECa works closely with Endo-ERN, ESPE and ESE
and the platforms it has developed have most recently been
adopted by the European Reference Network for Rare Bone
Conditions (ERN-BOND) and its related registry, the Eur-
opean Registry for Rare Bone and Mineral Conditions
(EuRR-Bone). The two main arms of the EuRRECa project
encompass—a CER that collects a common dataset and
clinician and patient reported outcomes and an electronic
surveillance system, the e-Reporting for Rare Endocrine
Conditions (e-REC) programme (Fig. 1).
EuRRECa receives guidance from Expert Working
Groups that align with the Main Thematic Groups of Endo-
ERN. This guidance flows through work packages (WP)
that review the needs of patients and parents, comply with
the highest ethical standards, evaluate the quality and
interoperability of datasets and combine them with patient-
centred outcomes (Fig. 2). Clear policies that are acceptable
to patients, researchers and industry for data governance
coupled with dissemination and knowledge exchange
through closely affiliated stakeholders will ensure that
EuRRECa is sustained beyond the current lifetime of the
project.
Stakeholders involved in the development
of EuRRECa
Stakeholders beyond the project group include patient and
parent groups, government organisations, European refer-
ence networks, national and European initiatives including
Orphanet and industry and pharma. Until now, in the field
of endocrine conditions, interaction between professional
societies, the pharmaceutical industry and registries held in
academic centres has been limited. EuRRECa has devel-
oped standard policies that provide equitable access and
have a system of quality assurance that fulfil the need of
industry and regulators. The involvement of patients and
parents of children with rare conditions in registries is also
vital and patient organisations such as EURORDIS
appreciate the need for internationally available, interoper-
able, high quality registries that have a ‘patient-centred’
approach. The framework structure of EuRRECa ensures
comprehensive patient representation in all of its working
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Fig. 1 The concept of the
European Registry for Rare
Endocrine Conditions
(EuRRECa)
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independent governing board (Fig. 2). In addition, there is a
work package dedicated for the needs of patients and par-
ents, with individuals from a multi-lingual and multi-disease
background. Professional societies such as ESPE and ESE
widely support EuRRECa and provide a valuable forum for
exchanging and disseminating information. Moreover, close
collaboration between adult and paediatric endocrinologists
has been evident through previous registry-based European
projects including EuroDSD, DSDnet, DSDlife and EU
TAIN (www.tain-project.org). Going forward, utilising the
model and resources that professional endocrine societies in
Europe already have in place for supporting registries for
rare endocrine conditions will be instrumental in ensuring
the long-term sustainability and capacity building for the
EuRRECa project.
The platform for e-reporting of rare
endocrine conditions (e-REC)
Many clinical and scientific networks for rare conditions
operate an electronic reporting system to capture activity as
well as to understand incidence, prevalence and natural
history of conditions, whilst supporting research [7, 8].
e-REC (https://eurreca.net/e-rec/) is an electronic reporting
system which allows continuous reporting of core indicators
of activity and enables clinical networks such as Endo-ERN
to embark on its stated mission of objectively mapping
conditions and related activity, providing a better under-
standing of the occurrence of the rare conditions covered
within Endo-ERN [5]. More recently, this list of conditions
has been extended to include those that are covered within
ERN-BOND. The platform was originally launched in 2018
and is open to all centres that look after people with such
conditions. The potential for e-REC to act as an agile and
adaptable tool for surveillance has also been illustrated by
its use since April 2020 on a joint project with the ESE’s
RD Committee for reporting new cases of COVID-19
infection in those with an existing endocrine or metabolic
condition.
In the current e-REC platform, users are asked to report
any new case of any of the conditions that have been
included in Endo-ERN, this process does not require
informed consent from patients. On reporting a case, no
personally identifiable information is collected and the form
itself takes <2 min for completion. The platform offers
several user benefits and these include a self-registration
link for new users, direct log-in to the website to view
dashboards and users are also able to select conditions and
age groups that they would like to report on. Multiple
reporters can be selected within each reporting centre,
however, it is not possible for another team member to sign
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Fig. 2 The European Registry for Rare Endocrine Conditions (EuRRECa) consortium. WP01-06: Work Packages 01–06
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up for the same condition/age group. The reporting months
remain open for a period of 3 months and users have the
option to report suspected and/or confirmed cases. The latter
is particularly useful in cases where genetic or biochemical
diagnostic confirmation is pending. Unique IDs for reported
cases are generated instantaneously and emailed to users to
be stored locally at reporting centres, linking cases to the
unique ID will enable clarification of diagnostic certainty at
a later stage. Users are able to view their reported cases and
results in their dashboard with the option of downloading
data in a CSV file format. The reported data are stored on a
secure server in the University of Glasgow. This project
complies with EU GDPR [9] and is approved by the
Information Governance authorities at the NHS Greater
Glasgow & Clyde Health Board and the National Research
Ethics Service in the UK.
The e-REC platform is openly publicised so that all
stakeholders including patients are fully aware of the
reporting process and information sheets including a public
information sheet are available in more than ten languages.
Data are available to all stakeholders following approval by
the Data Access Committee of the EuRRECa project.
The Core Registry
The EuRRECa Core Registry (https://eurreca.net/core-
registry/) has been operational since June 2019 and it col-
lects a core dataset that has been evaluated against existing
FAIR standards [10]. The fields have a high level of inter-
operability for a wide range of rare conditions including
those that are covered within Endo‐ERN and ERN-BOND
[5]. The fields that are used to collect core information
include the core data elements that are recommended by
European standards for data collection [11] and a high pro-
portion of them have universal identifiers. Details of the
standard operating procedures are available at the EuRRECa
project website (eurreca.net/data-access-process/). Clinicians
can enter patient data into the Core Registry after obtaining
consent from patients. Reference centres within Endo-ERN
may consider using the consent form provided by the ERN,
however, more detailed information sheets and consent forms
that have ethics and information governance approval have
been created by EuRRECa and are available in several lan-
guages. Those centres that recruit through a process of opt-
out consent can specify this information when a new record
is created irrespective of the nature of the consent process,
participating centres and clinicians are advised to seek local
information governance and ethics approval. Ethical approval
is also in place to facilitate the exchange of data in the CER
and other EuRRECa-approved registries. The data collected
in the registry will be used to improve clinical care as well as
research with data access governed by a Data Access
Committee. The results of any studies performed will be
disseminated widely and the registry advises participants on
other suitable studies.
Patients are able to access the registry to view their own
record, set preferences for data sharing and complete patient
reported outcomes (PROs); patients are required to provide
their email address to their clinician for online access and
this is captured on the registry consent form. PROs are
increasingly being used in registries to understand patient
experiences and preferences. As highlighted at the First
International Rare Diseases Research Consortium (IRDiRC)
Task Force Workshop on patient-centred outcome measures
(PCOMs), in rare disease research as well as clinical care,
quality of life data and PROs are particularly important
when well-defined, widely accepted clinical outcomes are
not available and a number of validated instruments already
exist [12, 13]. Within the CER, generic PROs are completed
using the age-specific EQ-5D tool (euroqol.org) and both
clinicians and parents can use the tool to report outcomes.
Work is also ongoing amongst the EuRRECa Expert
Working Groups to identify condition-specific PCOMs that
may be a combination of PROs and other measures
observed clinically or via biomarkers. Standardising the
development of PCOMs through a dedicated work package
and incorporating PROs into our platform will ensure that
the collection of PCOMs becomes routine enabling Endo-
ERN to achieve its objective of improving patient-centred
care for those with rare endocrine conditions.
Data access, data quality and data
governance
The EuRRECa project aims to promote good standards of
practice by adherence to the highest standards of data
security and the data collected in e-REC and the CER are
subject to stringent governance [14]. The project complies
with the UK Data Protection Act (2018) and General Data
Protection Regulation (GDPR 2016/679) and the e-REC
and the Core Registry have been approved by the UK
Research Ethics Service. In addition, all participating cen-
tres obtain their own local institutional approvals for using
the two registries.
The Data Access Committee (DAC) is composed of
members of the Project Governing Board responsible for
co-ordination, management, quality assurance, core out-
comes, patients, parents and ethics and a statistician. There
is also representation from ESPE and ESE. Members of the
expert working groups are co-opted depending on the
endocrine theme. The Committee has developed a Data
Access Policy which oversees the process for requesting
access to the data that are collected in e-REC and the CER [14].
Stakeholders request data by completing a Data Request
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Form and a Data Sharing Agreement. The request is
reviewed by the DAC who provide feedback to the appli-
cant, who may be asked to revise the request. Once
approved, data are released to the applicant. In some cases,
further information may be required and via the project
management team, they can ask for additional data or
clarification of data they have already received. This process
will lead to an improvement in the quality of the data held in
the registry. In addition, EuRRECa has a work package that
oversees Quality Assurance. This work package was
instrumental in ensuring the data being collected in the CER
adhere to FAIR principles. By using Orphacodes and
LOINC codes, the data are highly interoperable with other
registries that use the same approach. Data may be
requested for a number of reasons that may include con-
ducting an epidemiological survey for a particular condi-
tion, designing an additional questionnaire, appraising best
clinical practice or comparing outcome measures across
different conditions or centres. In all cases, supply of
data is dependent on feedback from the recipients in the
form of a report which is posted on the public area
of the website.
Summary and future direction
The EuRRECa project has incorporated the development of
a CER and an e-Reporting Programme for Rare Endocrine
Conditions, with adherence to the highest standards of data
security and information governance. These secure web-
based platforms facilitate the collection of standardised data
internationally, enabling multicentre collaborative research
to be performed. Work on this project is ongoing with
active developments from a clinical and research pro-
spective, including signposting Core Registry users to
Endo-ERN accredited disease registries. The lessons learnt
from this model can be applied to any large group of rare
conditions that require a common Core Registry and an
electronic surveillance system to capture activity, epide-
miology and natural history of these conditions.
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